Weekly Paclitaxel/Carboplatin/Bevacizumab as First Line Therapy for Triple Negative Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Carboplatin|DRUG: Bevacizumab|DRUG: Paclitaxel
Sponsor: Hellenic Oncology Research Group
Collaborators: University Hospital of Crete